Allergological Study of 565 Elderly Patients Previously Labeled as Allergic to Penicillins

Purpose: Elderly people thought to have an allergy to beta-lactams (BLs) may tolerate the drugs in subsequent exposures due to initial false labeling of allergies, the spontaneous loss of sensitivity to BLs over time or age-related decline in sensitization. As a result, they may be treated with less appropriate antibiotics, causing more side effects and entailing increased costs for health systems. The aim of this investigation was to assess whether patients in the third and fourth age with previously confirmed allergies to BLs had lost sensitization and could tolerate these antibiotics.

Patients and methods: Patients allergic to BLs were divided into group A (aged 60–79 years) and (aged ≥80 years). Clinical history, skin testing, drug challenge tests (DCT) and evaluation of resensitization were used to classify participants as showing immediate reactions, non-immediate reactions, or tolerance. We compared clinical entities, drugs involved, and final outcome by age group.

Results: Of 1362 cases evaluated, 565 underwent an allergological study. The skin was the most common organ involved. Anaphylaxis and side chain reactions were more frequent in group A (p<0.01), as were positive DCT. Classical benzylpenicillin determinants (benzylpenicilloyl and/or minor determinant mixture) were more frequent triggers in group B (p<0.01). Resensitization after challenge occurred in very few participants.

Conclusion: The risk for allergy to BLs decreases with age and a history of anaphylaxis by BLs is a predictor of positive results in skin tests (ST). Both immunoglobulin E (IgE) and T-cell mediated responses can disappear in elderly people, who can develop tolerance to these antibiotics. These results are of clinical relevance to patients who need to be treated with antibiotics from this family.

Keywords: drug allergy, beta-lactams, cephalosporins, cross-reactivity, aging, immunosenescence, diagnosis

Introduction

BLs antibiotics comprise five major families: penicillins, cephalosporins, monobactams, carbapenems, and clavams. These drugs are the most frequently involved in reactions IgE-mediated, with an estimated prevalence of 5% to 10% in the general population. More than 95% of the people who report allergy to BLs have good tolerance.

This apparent contradiction may have different explanations: drug side effects that are not by themselves allergic in nature, the attribution of the allergic reaction to these antibiotics when they are caused by other drugs, or the spontaneous loss of sensitivity to BLs over time.

An incorrect diagnosis of BL allergy may lead to the prescription of second-line antibiotics, which can be more toxic, be related to the development of multi-resistant bacterial strains and to the increase in costs.
One problem of major concern is antibiotic prescription in the elderly, because of their immunological decline, this group is more susceptible to systemic infections. Whether this decline has an impact on the IgE system is unconfronted, but it is reasonable to assume that this decline may not only affect the IgG, IgA, and IgM antibody response.

Preliminary evidence from our group indicates that older people have a lower prevalence of BL allergy than the general population. Based on these observations, our aim was to estimate the prevalence before and after an allergological work-up in elderly patients who were referred to our centers for a study on BL allergy after having been previously diagnosed as allergic in different medical services including Geriatrics, Internal Medicine, and Family Medicine.

In this study, we tested the hypothesis that impaired IgE response could be another mechanism for tolerance after drug re-exposure and proved that allergy to BLs decreases with age, probably because of both humoral and cellular immunosenescence.

Materials and Methods

Patients

We studied patients aged 60 years or older with a history of hypersensitivity reactions (HSRs) to BLs, who were admitted in the Internal Medicine Service or the Infectious Diseases Unit, or attended for evaluation in the Allergy Service of the Alicante University General Hospital (Alicante, Spain) and Infanta Leonor University Hospital (Madrid, Spain) from November 2015 to November 2017. Patients were classified by age into two groups, according to cutoffs reported elsewhere: group A, 60 to 79 years; and group B, 80 years or older.

Strategy for Recruitment

Cases included in the study were recruited from two groups:

1. Patients admitted in the participating services and either previously labeled as allergic to BL or labeled as having HSR to BLs during the hospital stay.
2. Patients with a history of drug HSR to BLs and referred to the outpatient allergy clinic for evaluation.

Clinical History

We undertook a detailed clinical history following the guidelines of the expert group of the European Academy of Allergy and Clinical Immunology (EAACI). We also considered the time interval between drug intake and onset of symptoms, duration of treatment before the reaction occurred, and response to treatment.

Classification of Reactions

Following the EAACI guidelines, immediate hypersensitivity reactions (IHSR) were defined as those that appeared within 20 mins of drug intake and lasted no longer than 1 hr. Involvement of two or more organs was classified as anaphylaxis.

Non-immediate hypersensitivity reactions (NIHR) usually appear at about 24 to 48 hrs but may present as early as 1 hr after drug intake. Limited organ-specific reactions like hepatitis, renal failure, pneumonitis, anemia, neutropenia, and thrombocytopenia were not included in our study.

Before undertaking the study, all patients and/or their authorized representatives were informed of the potential risks and benefits of skin testing and DCT, and they signed written informed consent to participate. The study conforms to the standards of the Declaration of Helsinki.

The protocol was approved by the Hospital Ethics Committee (CEIC PI2014/53).

Skin Testing

ST began by prick test that was considered positive if a wheal greater than 3 mm appeared surrounded by erythema within 20 mins of application. If negative, we proceeded to intradermal testing with 0.02 mL of BL solution, repeating the reading at the same time interval. Different 10-fold dilutions were used in cases with severe symptoms. Reactions were considered positive if the initial injection papule increased in size by 3 mm or more. In case of a clinical history indicative of a NIHSR, a reading took place at 24 and 48 hrs after skin testing. In all cases, we advised patients to monitor the delayed response for up to 1 week after testing.

Reagents for Skin Testing

ST was carried out in the forearm as previously reported with the following penicillin allergic determinants: benzylpenicilloyl-poly-L-lysine (BPO-PPL 5×10^{-5}M) and minor determinant mixture (MDM 2×10^{-2}M) (provided by Diater, Madrid, Spain); penicillin G (10,000IU/mL: ERN Laboratories); ampicillin (20mg/mL: Normon Laboratories); amoxicillin (20mg/mL: GSK Laboratories); amoxicillin/clavulanic acid (20mg/mL: Normon Laboratories); cefazolin (20mg/mL: Normon Laboratories); cefotaxime (20mg/mL: Normon Laboratories).
Laboratories); and meropenem (20mg/mL: Kern Pharma Laboratories). In addition, clavulanic acid (5mg/mL and 20mg/mL: Diater, Madrid, Spain); ceftriaxone (20mg/mL: Normon Laboratories); cefuroxime (20mg/mL: Normon Laboratories); imipenem/cilastatin (20mg/mL: Pfizer, S.L.); piperacillin/tazobactam (20mg/mL: Mylan); and cloxacillin (20mg/mL: Normon Laboratories) were also tested when one of them was the culprit drug.

The specificity of the drugs included above was assessed by testing a matched control group with previously established good tolerance. These concentrations proved to be non-irritant in a group of 20 patients with similar age and clinical entities as study participants.

For the non-commercially available diagnosis reagents, testing solutions were prepared by the hospital pharmacy service by diluting them in saline under sterile conditions according to the manufacturer’s recommendations. Each vial was used on the same day it was prepared.

Serum Collection
Venipuncture was used to extract 10 mL of blood for sera. All samples were maintained at ~80ºC until analyzed.

In vitro Total IgE and Specific IgE (sIgE) Antibodies
Total IgE and sIgE to penicilloyl G, penicilloyl V, ampicilloyl, amoxicilloyl, and cefaclor were determined using commercially available immunoassays following the manufacturer’s instructions (Elecsys IgE II Immunoassay, Roche Diagnostics, USA and ImmunoCAP, Thermo Fisher Scientific, USA, respectively), values of total IgE exceeding 100 IU/mL were considered high and sIgE>0.35 kU/L were considered positive.

Drug Challenge Test
The performance of DCT was decided based on the clinical history and ST results. In patients with medical conditions that limited the oral route, the challenge used the intravenous one, as detailed below.

According to the culprit drug and treatment needs, DCTs were done with penicillin V, amoxicillin, ampicillin, amoxicillin/clavulanic acid, cloxacillin, cefditoren, cefuroxime or meropenem. In those experiencing a reaction with benzyl-penicillin, we performed the DCT with amoxicillin unless the patient needed to be treated with it, as we considered that amoxicillin is the most commonly used BL and is valid to identify BPO-cross reactions and specific side chain reactions.29

In patients who reacted to other BLs, after obtaining negative results in the ST with the determinants described above, we proceeded with skin testing of the culprit drug. If this result was also negative, we undertook DCT.

In patients with a clinical history suggesting an IgE-mediated response, a single-blind placebo-controlled DCT (oral or intravenous) was performed, starting with 1/100 of the therapeutic dose, followed by a 10-fold increase in dose until reaching the cumulative dose of 500 mg. In patients with good tolerance, the diagnosis of allergy was ruled out.

If the clinical history was suggestive of a NIHSR, a negative skin test was followed by a single oral dose of 100 mg. If no response appeared within 48 hrs, we proceeded with the full therapeutic dose, as described previously.30 If the DCT was negative, treatment with therapeutic doses of the same medication was administered to the patients for 3 days.31 If the patient had no reaction during or following treatment, the diagnosis of allergy to BLs was ruled out.

As described by Park and others,26,32,33 patients with positive ST were not challenged because of the high risk of inducing a reaction. Each patient was carefully monitored during the whole procedure, with facilities and trained staff for managing any possible undesired and unexpected reactions. Patients with an HSR strongly suggestive of being IgE-mediated, with negative ST and tolerance of DCT with the selected BL, were reevaluated at 4 to 6 weeks to exclude a booster response and/or resensitization. Following published guidelines, we did not test patients with suspected severe NIHSR due to BLs.14,34,35

Statistical Analysis
Descriptive statistical tests were applied to assess patient characteristics, with continuous values expressed as means (standard deviation, SD) or medians (interquartile $Q_{25-75}$, IQ$_{25-75}$). Differences between groups were evaluated using the Student’s t-test for unpaired data when the sample followed a normal distribution, or using the Mann-Whitney U-test for non-parametric variables. For paired samples that did not follow a normal distribution, the Wilcoxon test was used. The chi-squared test or Fisher’s exact test was applied to analyze categorical variables. The odds of being truly allergic was assessed by means of multiple logistic regression analysis.
Little’s MCAR test was used to determine if the missing data followed the same distribution as available data. Multiple imputations by chained equations were performed, and a multivariable logistic regression model fitted.

The SPSS program version 25 (IBM, USA) and the R package version 3.5.1 were used to perform statistical analyses; \( p \) values <0.05 were considered significant.

**Results**

Of the 1362 patients who reported allergy to BLs, 62% agreed to participate, and the allergological study was completed in 565 (286 in group A and 279 in group B (Figure 1). Patients’ characteristics are shown in Table 1. There were more women than men in both groups (\( p = 0.03 \)). The time between occurrence of the HSR and performance of the study was shorter in group A than in group B (median 5 years versus 30 years; \( p < 0.01 \)).

An allergist had previously evaluated and confirmed BL allergy in 22 patients in group A and 7 in the group B. Of these, 16 and 4 cases, respectively, were IHCSR and the others presented NIHSR.

A total of 175 patients (93% of whom belonged to group B) including some of those who were previously confirmed as allergic were treated with a BL at some time before being studied by us, despite being labeled as allergic.

Clinical data (Table 1) showed that 88.8% of patients from group A and 54.5% from group B provided detailed information about the symptoms that occurred in the initial HSR, allowing us to classify the reactions as IHCSR and NIHSR. Precise information of the reactions was not available in 11.2% of patients in group A and 45.6% in group B (\( p<0.01 \)).

According to the clinical history, skin was the most commonly involved organ (Figure 2). Urticaria was the most frequent clinical manifestation in group A (33.2%) and maculopapular exanthema (MPE) in group B (20.8%). Anaphylaxis was reported in 15.4% of patients in group A and 3.2% in group B (\( p<0.01 \)).

The BLs involved in the HSR are shown in Table 2. There was a clear difference in the culprit drug between groups: amoxicillin, amoxicillin–clavulanic acid and ampicillin were more frequent in group A (54.5%; \( p<0.01 \)), while benzylpenicillin was more frequent in group B (59.8%; \( p<0.01 \)).

ST were positive in 17.8% of the 285 group A patients, and in 2.9% of the 267 group B patients (\( p<0.01 \)). The determinants involved in the respective groups were mainly major and/or minor benzylpenicillin determinants (39.2% versus 87.5%; \( p<0.01 \)) and amoxicillin and/or ampicillin (39.2% versus 12.5%; \( p<0.01 \)). A small proportion (7.8%) of cases in group A presented positive results on ST to cephalosporins, compared to none in group B. Only 2% of the group A participants were ST positive to clavulanic acid (Tables 3 and 4).

Regarding the clinical presentation in patients with positive ST, anaphylaxis was the most frequent in both groups (48% and 62.5%, respectively). The logistic
regression analysis showed that a history of anaphylaxis is a predictor of positive results in ST ($p<0.01$).

DCT was done in 235 patients of group A (99.6% by oral route) and in 270 patients of group B (89.4% by oral route and 10.4% by intravenous route). It was well tolerated in 89.4% and 97.8%, respectively ($p<0.01$). The drugs used in the challenges are shown in Table 5.

Reactions during DCT were more frequent in group A (10.6% versus 2.2%, respectively, $p=0.007$). We detected sIgE in 6 of the 29 patients (3 in each group) who had previously been diagnosed as allergic but had negative skin tests and good tolerance in DCT.

Retest was done in 128 patients (84 in group A and 44 in group B) and only two patients (1.6%) became positive. One was in a 63-year-old man with an episode of immediate angioedema from 40 years earlier, who had good tolerance in the DCT to amoxicillin (culprit drug) and became positive to this antibiotic after the challenge. The second case was an 85-year-old woman with a history of dizziness after being treated with benzylpenicillin from 40 years earlier, who developed an immediate urticaria during a DCT with penicillin V and became positive to penicillin on ST. The reaction was controlled with intravenous antihistamines.

Symptoms compatible with NIHSR were reported in 156 patients: 41.3% of group A and 33.6% of group B. MPE was the most frequent clinical entity reported in both groups (26.7% and 29.4%, respectively), followed by non-immediate urticaria (38.1% and 31.4%) and non-immediate angioedema (18.1% and 5.9%). ST were negative on delayed reading in 94.9% of these cases. DCT was performed in 99.3% of patients, observing a positive non-immediate response in 16 patients in group A (8 MPE, 7 non-immediate urticaria, and 1 angioedema) and 4 patients in group B (3 MPE and 1 erythroderma) ($p=0.007$). In addition, one patient in group A developed an urticaria 50

---

**Table 1 Participants’ Characteristics**

| Variables                  | Group A (n = 286) | Group B (n = 279) | p value |
|----------------------------|------------------|------------------|---------|
| Age, years, median (IQ 25-75) | 67 (10)         | 85 (6)           |         |
| Women, n (%)                | 189 (66.1)       | 207 (74.2)       | 0.03    |
| Place of origin, n (%)      |                  |                  |         |
| Spain                      | 283 (98.9)       | 263 (94.3)       | 0.02    |
| Other countries             | 3 (1)            | 16 (5.7)         |         |
| Atopy, n (%)                | 107 (37.4)       | 48 (17.2)        | <0.01   |
| Allergy to other drugs, n (%) | 69 (24.1)      | 59 (21.1)        | 0.35    |
| Years since the initial HSR, median (IQ 25-75) | 5 (34.5) | 30 (30)          | <0.01   |
| Timing of reaction, n (%)   |                  |                  |         |
| Immediate                  | 149 (52.1)       | 101 (36.2)       | 0.12    |
| Non-immediate               | 105 (36.7)       | 51 (18.3)        |         |
| Do not remember             | 32 (11.2)        | 127 (45.6)       | <0.01   |
| Skin tests, n (%)           |                  |                  |         |
| Positive                   | 51 (17.8)        | 8 (2.9)          | <0.01   |
| Negative                   | 234 (81.8)       | 255 (91.4)       |         |
| Inhibited/not done          | 1 (0.3)          | 16 (5.7)         |         |
| Allergic, n (%)             | 77 (26.9)        | 15 (5.4)         | <0.01   |

Notes: *Other European and South American countries. **Allergic is defined by patients with positive skin tests or drug challenge tests.

Abbreviations: IQ 25-75, interquartile 25-75; HSR, hypersensitivity reaction.

---

**Table 2 Beta-Lactams Involved in the Initial HSR by Age Group**

| Culprit Drug                | Group A (N = 286 n (%)) | Group B (N = 279 n (%)) | p value |
|-----------------------------|-------------------------|-------------------------|---------|
| Benzylpenicillin            | 96 (33.6)               | 167 (59.8)              | <0.01   |
| Amoxicillin                 | 82 (28.7)               | 20 (7.2)                | <0.01   |
| Amoxicillin/clavulanic acid | 73 (25.5)               | 18 (6.5)                |         |
| Ampicillin                  | 1 (0.3)                 | 0                       |         |
| Cloxacillin                 | 1 (0.3)                 | 3 (1.1)                 | 0.30    |
| Ceftriaxone                 | 20 (7)                  | 4 (1.4)                 | 0.01    |
| Cefazoline                  | 2 (0.7)                 | 0                       | 0.16    |
| Cefuroxime                  | 2 (0.7)                 | 0                       | 0.16    |
| Meropenem                   | 0                       | 4 (1.4)                 | 0.04    |
| Imipenem                    | 0                       | 2 (0.7)                 | 0.15    |
| Piperacillin/tazobactam     | 1 (0.3)                 | 1 (0.4)                 | 0.98    |
| Does not remember           | 8 (2.8)                 | 60 (21.5)               | <0.01   |

---

**Figure 2** Clinical manifestations of the initial hypersensitivity reactions. The graph shows the symptoms of the HSR based on which the diagnosis of BL allergy was established. Being the most frequent cutaneous symptoms in both groups, while anaphylaxis was more frequent in group A. On the other hand, the majority of patients who did not remember the symptoms were those of group B.
| #  | Age | Timing (Years) | Culprit | Clinical | ST | Total IgE (U/mL) | IgE PG (kU/L) | IgE PV (kU/L) | IgE Amy (kU/L) | IgE AXy (kU/L) | IgE CE (kU/L) | DCT Drug | DCT Results |
|----|-----|----------------|---------|----------|----|-----------------|---------------|---------------|---------------|---------------|---------------|----------|------------|
| 1  | 61  | 2              | AX/clv  | Pru      | +AX| 66.9            | 0.03          | 0.04          | 0             | 0.05          | 0.01          | NO       |            |
| 2  | 63  | 0.25           | Cefur   | AE       |    | 189             | 0             | 0             | 0             | 0             | 0             | Cefur    | +D         |
| 3  | 61  | 0.5            | AX      | Ana      | +AX+AM| 212.2           | 0.01          | 0.03          | 0             | 0.02          | 0.03          | NO       |            |
| 4  | 78  | 0.08           | AX/clv  | Urt      |    | 2               | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | NO       |            |
| 5  | 75  | 0.08           | AX/clv  | Pru      | +Crv | 1871            | 0             | 0             | 0             | 0             | 0             | PN       |            |
| 6  | 74  | 50             | PN      | NR       | +PN | 27              | 0.33          | 0             | 0.22          | 0             | 0             | NO       |            |
| 7  | 71  | 4              | Ceftx   | MPE      |    | ND              | ND            | ND            | ND            | ND            | ND            | ND       | NO         |
| 8  | 71  | 0.16           | AX      | Ana      | +AX | 156             | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | NO       |            |
| 9  | 73  | 0.08           | PN      | Urt      | +PN | 68              | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | NO       |            |
| 10 | 72  | 15             | AX      | Urt      | +AX | 175             | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | NO       |            |
| 11 | 60  | 0.08           | AX      | Ana      | +PN | 78              | <0.1          | <0.1          | 0.49          | <0.1          | <0.1          | NO       |            |
| 12 | 77  | 0.08           | AX      | Urt      | +AX | 88              | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | NO       |            |
| 13 | 63  | 40             | PN      | Pru      | +PN | 5               | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | NO       |            |
| 14 | 68  | 0.08           | AX      | Urt      |    | 26              | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | AX       | +D         |
| 15 | 68  | 0.08           | AX/clv  | Urt      |    | 4               | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | AX/clv   | +I         |
| 16 | 76  | 0.08           | AX/clv  | Ana      | +PN | 57              | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | NO       |            |
| 17 | 62  | 0.5            | AX/clv  | Ana      | +PN+AX| 139             | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | NO       |            |
| 18 | 67  | 0.25           | AX/clv  | Urt      |    | 15              | <0.1          | <0.1          | <0.1          | <0.1          | <0.1          | AX       | +D         |
| 19 | 61  | 20             | AX      | Ana      | +AX | 27              | 0             | 0             | 0.14          | 0             | 0             | NO       |            |
|   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 70 | 0.08 | AX/clv | MPE | – | 27 | 0 | 0 | 0 | 0 | 0 | AX | +D |
| 21 | 60 | 0.08 | AX | AE | – | 1172 | 0.04 | 0.01 | 0.03 | 0.01 | 0.01 | PN | +D |
| 22 | 60 | 0.5 | AX | AE | +AX | 193.5 | 0.07 | 0.07 | 0 | 0.05 | 0.01 | NO |   |
| 23 | 73 | 30 | PN | Ana | + PPL + PN | 74 | 0 | 0 | 0 | 0 | 0 | NO |   |
| 24 | 72 | 0.08 | AX | Urt | + PN | 633 | 0 | 0 | 0 | 0 | 0 | NO |   |
| 25 | 68 | 0.08 | AX/clv | Urt | – | 46 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | AX | +D |
| 26 | 64 | 0.08 | AX/clv | Ana | + PN | 151 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | NO |   |
| 27 | 77 | 0.5 | AX/clv | Urt | + PN | 30 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | NO |   |
| 28 | 60 | 0.08 | AX | Ana | + AX | 40 | 0 | 0 | 0 | 0 | 0 | NO |   |
| 29 | 64 | 26 | AX | Ana | + PN | 149 | 0 | 0 | 0 | 0 | 0 | NO |   |
| 30 | 67 | 60 | AX | NR | – | 374 | 0 | 0 | 0 | 0 | 0 | AX | +D |
| 31 | 67 | 20 | NR | Urt | – | ND | ND | ND | ND | ND | ND | PN | +I |
| 32 | 74 | 40 | NR | Urt | + PN + AX + AM | 12 | 0 | 0 | 0 | 0 | 0 | NO |   |
| 33 | 61 | 0.3 | AX/clv | Pru | + PN + AX + AM | 82.6 | 0.01 | 0 | 0 | 0.23 | 0 | NO |   |
| 34 | 61 | 40 | PN | Ana | – | 65 | 0 | 0 | 0 | 0 | 0 | AX | +D |
| 35 | 65 | 0.08 | AX/clv | Ana | + PPL + PN | 42 | 0 | 0 | 0 | 0 | 0 | NO |   |
| 36 | 69 | 0.08 | AX/clv | Urt | + PPL | 18 | 5.54 | 4.86 | 4.15 | 1.35 | ND | NO |   |
| 37 | 71 | 0.08 | AX | MPE | – | 7 | 0 | 0 | 0 | 0 | 0 | AX | +D |
| 38 | 70 | 2 | AX/clv | MPE | – | 78 | <0.1 | <0.1 | <0.1 | <0.1 | <0.1 | AX/clv | +D |
| 39 | 63 | 0.08 | AX | MPE | – | 212 | 0 | 0 | 0 | 0 | 0 | AX | +D |

(Continued)
| # | Age (Yrs) | Timing (Years) | Culprit     | Clinical | ST | DCT Drug | DCT Results | Total IgE (U/mL) | IgE CE (kU/L) | IgE PG (kU/L) | IgE AXy (kU/L) | IgE ARny (kU/L) | IgE PV (kU/L) | Retest | Remarks
|---|----------|---------------|------------|----------|----|----------|-------------|----------------|--------------|--------------|---------------|----------------|--------------|--------|--------
| 40 | 75       | 0.08          | AM         | MPE      | +AX| +AX/Div  | +AX         | 6.86           | 0.07         | 0.07         | 0.1           | <0.1          | <0.1       | NO     | Retest
| 41 | 69       | 0.08          | AX/Div     | Ana      | -  | -         | -            | 5.08           | <0.1         | <0.1         | <0.1          | <0.1          | <0.1       | NO     | Retest
| 42 | 61       | 0.08          | AX/Div     | Urt      | +AX| +AX/Div  | +AX         | 6.3            | 1.17         | 0.03         | 0.02          | 0.02          | 0.02       | NO     | Retest
| 43 | 63       | 0.08          | AX         | AE       | -  | -         | -            | 6              | 0            | 0            | 0             | 0             | 0          | NO     | Retest
| 44 | 65       | 0.08          | AX/Div     | Ana      | -  | -         | -            | 117.5          | 0            | 0            | 0             | 0             | 0          | NO     | Retest
| 45 | 67       | 0.08          | AX/Div     | Urt      | +AX| +AX/Div  | +AX         | 6.3            | 0            | 0            | 0             | 0             | 0          | NO     | Retest
| 46 | 70       | 0.08          | AX/Div     | Ana      | -  | -         | -            | 3.03           | 0            | 0            | 0             | 0             | 0          | NO     | Retest
| 47 | 70       | 0.08          | AX/Div     | MPE      | +AX| +AX/Div  | +AX         | 2.9            | 0            | 0            | 0             | 0             | 0          | NO     | Retest
| 48 | 70       | 0.08          | AX/Div     | Ana      | -  | -         | -            | 1.02           | 0            | 0            | 0             | 0             | 0          | NO     | Retest
| 49 | 73       | 0.08          | AX/Div     | MPE      | +AX| +AX/Div  | +AX         | 6              | 0            | 0            | 0             | 0             | 0          | NO     | Retest
| 50 | 61       | 0.08          | AX         | Urt      | -  | -         | -            | 9.51           | 0.08         | 0.03         | 0.04          | 0.03          | 0.04       | NO     | Retest
| 51 | 73       | 0.08          | AX         | Urt      | -  | -         | -            | 5.84           | 0.08         | 0.03         | 0.04          | 0.03          | 0.04       | NO     | Retest
| 52 | 77       | 0.08          | AX         | Urt      | +PPL| +PML    | +PML         | 2.037          | 5.84         | 0.08         | 0.03          | 0.04          | 0.03       | NO     | Retest
| 53 | 70       | 0.08          | AX         | Urt      | +PN | +PN     | +PN          | 102            | 0            | 0            | 0             | 0             | 0          | NO     | Retest
| 54 | 67       | 0.08          | AX         | Urt      | +PN | +PN     | +PN          | 6              | 0            | 0            | 0             | 0             | 0          | NO     | Retest
| 55 | 72       | 0.08          | AX         | Urt      | +PPL| +PPL    | +PPL         | 58             | 0.08         | 0.03         | 0.04          | 0.03          | 0.04       | NO     | Retest
| 56 | 70       | 0.08          | AX         | Urt      | +PPL| +PPL    | +PPL         | 58             | 0.08         | 0.03         | 0.04          | 0.03          | 0.04       | NO     | Retest
| 57 | 60       | 0.08          | AX         | Urt      | +PN | +PN     | +PN          | 58             | 0.08         | 0.03         | 0.04          | 0.03          | 0.04       | NO     | Retest
| 58 | 76       | 0.08          | AX         | Urt      | +PPL| +PPL    | +PPL         | 58             | 0.08         | 0.03         | 0.04          | 0.03          | 0.04       | NO     | Retest
| 59 | 60       | 0.08          | AX         | Urt      | +PPL| +PPL    | +PPL         | 58             | 0.08         | 0.03         | 0.04          | 0.03          | 0.04       | NO     | Retest

*Note: AM = Amoxicillin, MPE = Mefloquine, AX = Allopurinol, Ana = Analgesic, Urt = Urticaria, PN = Penicillin, MD = Methylprednisolone, +D = Drug Challenge, ND = Not Done, AX = Allopurinol, MPE = Mefloquine, +AX = Allopurinol, +MPE = Mefloquine, +PPL = Penicillin, +MDM = Methylprednisolone.*
| # | Patient Identification Number | Challenge | Skin Test | Challenge | Challenge | Challenge | Challenge | Challenge | Challenge | Challenge | Challenge |
|---|-----------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| 61 | 67 | 0.16 | AX | + AX | 20 | AX | + AX | 0.08 | AX | + AX | 0.08 | AX | + AX |
| 62 | 78 | 0.08 | AX | - AX | - AX | - AX | - AX | - AX | - AX | - AX | - AX | - AX |
| 63 | 61 | 0.8 | Cefazo | + Cefazo | 30 | Cefazo | + Cefazo | 0.04 | Cefazo | + Cefazo | 0.08 | Cefazo | + Cefazo |
| 64 | 70 | 0.08 | AX | + AX | 0.08 | AX | + AX | 0.08 | AX | + AX | 0.08 | AX | + AX |
| 65 | 62 | 20 | AX | + AX | 20 | AX | + AX | 20 | AX | + AX | 20 | AX | + AX |
| 66 | 67 | 0.08 | AX | + AX | 0.08 | AX | + AX | 0.08 | AX | + AX | 0.08 | AX | + AX |
| 67 | 69 | 2 | AX/clv | + AX/clv | 2 | AX/clv | + AX/clv | 2 | AX/clv | + AX/clv | 2 | AX/clv | + AX/clv |
| 68 | 63 | 0.5 | AX/clv | + AX/clv | 0.5 | AX/clv | + AX/clv | 0.5 | AX/clv | + AX/clv | 0.5 | AX/clv | + AX/clv |
| 69 | 71 | 0.08 | AX | + AX | 0.08 | AX | + AX | 0.08 | AX | + AX | 0.08 | AX | + AX |
| 70 | 75 | 0.5 | AX/clv | + AX/clv | 0.5 | AX/clv | + AX/clv | 0.5 | AX/clv | + AX/clv | 0.5 | AX/clv | + AX/clv |
| 71 | 60 | 0.08 | AX/dx | + AX/dx | 0.08 | AX/dx | + AX/dx | 0.08 | AX/dx | + AX/dx | 0.08 | AX/dx | + AX/dx |
| 72 | 72 | 0.05 | AX | + AX | 0.05 | AX | + AX | 0.05 | AX | + AX | 0.05 | AX | + AX |
| 73 | 70 | 0.5 | AX | + AX | 0.5 | AX | + AX | 0.5 | AX | + AX | 0.5 | AX | + AX |
| 74 | 73 | 0.16 | AX | + AX | 0.16 | AX | + AX | 0.16 | AX | + AX | 0.16 | AX | + AX |
| 75 | 63 | 5 | Cefazo | + Cefazo | 5 | Cefazo | + Cefazo | 5 | Cefazo | + Cefazo | 5 | Cefazo | + Cefazo |
| 76 | 61 | 0.5 | AX/clv | + AX/clv | 0.5 | AX/clv | + AX/clv | 0.5 | AX/clv | + AX/clv | 0.5 | AX/clv | + AX/clv |
| 77 | 79 | 40 | PN | + PN | 40 | PN | + PN | 40 | PN | + PN | 40 | PN | + PN |

Note: Bold characters indicate positive results. Abbreviations: +, positive; -, negative; INH, inhibited; +D, positive challenge with non-immediate HSR; +I, positive challenge with immediate hypersensitivity reaction; ST, skin tests; PN, penicillin; AX, amoxicillin; AX/clv, amoxicillin/clavulanic acid; AXy, amoxicilloyl; AXa, amoxycillin; ANA, anaphylaxis; AZL, azlocillin; CBT, cefotaxime; CHF, challenge; CH, challenge; MPE, maculopapular exanthema; Diz, dizziness; NO, challenge not done due positive skin test results; NR, does not remember; ND, not done.
|   | Age  | Timing (Years) | Culprit  | Clinical | ST | Total IgE (U/mL) | IgE PG (kU/L) | IgE PV (kU/L) | IgE Amy (kU/L) | IgE AXy (kU/L) | IgE CE (kU/L) | DCT Drug | DCT Results |
|---|------|---------------|----------|----------|----|-----------------|---------------|--------------|---------------|---------------|--------------|----------|-------------|
| 1 | 86   | 0.5           | Ceftx    | MPE      | −  | 421.4           | 0.01          | 0.04         | 0.05          | 0.08          | 0.02         | Cefur     | +D          |
| 2 | 81   | 0.5           | AX       | MPE      | −  | 118.3           | 0             | 0.01         | 0.03          | 0.04          | 0.03         | AX        | +D          |
| 3 | 82   | 30            | PN       | Ana      | +   | 985.2           | 0.62          | 0.52         | 0.32          | 0.26          | 0.07         | NO        |             |
| 4 | 93   | 30            | NR       | Ana      | +   | 255.7           | 0.15          | 0.15         | 0.3           | 0.18          | 0.11         | NO        |             |
| 5 | 83   | 30            | PN       | Ana      | +   | ND              | ND            | ND           | ND            | ND            | ND           | NO        |             |
| 6 | 81   | 60            | PN       | Ana      | +   | 254.5           | 0.22          | 0.21         | 0             | 0.09          | 0.03         | NO        |             |
| 7 | 85   | 40            | PN       | Diz      | −   | 2               | 0             | 0            | 0.18          | 0             | 0            | PN        | +I          |
| 8 | 84   | 30            | PN       | Pru      | +   | 4               | <0.1          | <0.1         | <0.1          | <0.1          | <0.1         | NO        |             |
| 9 | 82   | 30            | PN       | AE       | −   | 9               | <0.1          | <0.1         | <0.1          | <0.1          | <0.1         | PN        | +I          |
| 10| 83   | 0.17          | Pip/tb   | MPE      | −   | 24              | <0.1          | <0.1         | <0.1          | <0.1          | <0.1         | PN        | +D          |
| 11| 82   | 50            | PN       | Diz      | +   | 37              | <0.1          | <0.1         | <0.1          | <0.1          | <0.1         | NO        |             |
| 12| 81   | 30            | NR       | NR       | +   | 10              | <0.1          | <0.1         | <0.1          | <0.1          | <0.1         | NO        |             |
| 13| 82   | 0.25          | AX/clv   | MPE      | −   | 9               | <0.1          | <0.1         | <0.1          | <0.1          | <0.1         | AX/clv   | +I          |
| 14| 88   | 0.08          | AX/clv   | Ana      | ND  | 23              | 2.67          | 2.12         | 7.41          | 6.43          | ND           | NO        |             |
| 15| 80   | 0.08          | AX       | Ana      | +   | 12              | <0.1          | <0.1         | <0.1          | <0.1          | <0.1         | NO        |             |

Note: Bold characters indicate positive results.

Abbreviations: #, Patient identification number; -, negative; +, positive; INH, inhibited; +D, positive challenge with non-immediate HSR; +I, positive challenge with immediate hypersensitivity reaction; ST, skin tests; PN, penicillin; PPL, poly-L-lysine AM, ampicillin; AX, amoxicillin; AX-clv, amoxicillin/clavulanic acid; Pip/tb, piperacillin/tazobactam; Cefazo, cefazoline; Cefota, cefotaxime; Cefur, cefuroxime; Cefix, cefixime; Cefdt, cefditoren; Ceftz, ceftazidime; Clox, cloxacillin; ME, meropenem; IgE, immunoglobulin E; PG, penicilloy G; PV, penicilloy V; AMy, ampicilloy; AXy, amoxicilloy; CE, cefaclor; Ana, anaphylaxis; AE, angioedema; Pru, pruritus; Urt, urticaria; MPE, maculopapular exanthema; Diz, dizziness; CH, challenge; NO, challenge not done due positive skin test results; NR, does not remember; ND, not done.
min after drug intake, which we considered an immediate HSR. All cases were controlled with corticoids and anti-histamines at 12 hrs to 24 hrs, and complete clearance was achieved within 72 hrs. Of note is that the previously confirmed cases in our study developed good tolerance.

Final diagnosis of allergy to BL was based on the results of skin testing and DCT, and was made in 77 (26.9%) patients in group A and 15 (5.4%) patients in group B (p<0.01). Multivariable analysis showed that, after adjusting for sex, atopy, allergy to other drugs, and sIgE to amoxicilloyl, younger age is an independent risk factor for allergy to BL (p<0.01).

### Discussion

Our aim was to confirm if patients’ past BL allergy still remained and to establish the relationship between decreased immune response and the presence of allergy. Based on current knowledge regarding immunity in the very elderly, our hypothesis was that age-related decline of both cellular and humoral immune response could result in tolerance to BLs in patients who had previous allergies with IgE- or T cell-mediated reactions. For this purpose, we compared two groups of patients, the first aged 60 to 79 years, and the second aged 80 or older. Participants had been labeled as allergic, so we evaluated

| Table 5 Drug Challenges and Antibiotic Selected for Them |
|---------------------------------------------------------|
| **Culprit Drug** | **Group A; N = 286** | **Total** | **Group B; N =279** | **Total** |
| n | Drug Challenge | n | Drug Challenge | |
| Penicillin | 96 | Amoxicilloyl | 71 | Amoxicilloyl | 167 | Penicillin | 2 |
| | | Amoxicilloyl/clavulanic acid | 18 | Amoxicilloyl | 107 | Amoxicilloyl | 49 |
| | | CH not donea | 7 | Amoxicilloyl | 4 | Amoxicilloyl | 5 |
| | Amoxicilloyl | 82 | Penicillin | 1 | Amoxicilloyl | 13 | Amoxicilloyl | 3 |
| | | Amoxicilloyl | 52 | Amoxicilloyl | 3 | Amoxicilloyl | 3 |
| | | Amoxicilloyl/clavulanic acid | 10 | CH not donea | 1 |
| | | CH not donea | 19 | CH not donea | |
| Amoxicilloyl/ clavulanic acid | 73 | Amoxicilloyl | 5 | Amoxicilloyl/clavulanic acid | 18 | Amoxicilloyl/clavulanic acid | 17 |
| | | Amoxicilloyl | 50 | CH not donea | 1 |
| | | Amoxicilloyl/clavulanic acid | 18 | CH not donea | 1 |
| | Ampicillin | 1 | CH not donea | 1 | |
| | Cloxacillin | 1 | CH not donea | 1 | 3 | Cloxacillin | 3 |
| | Ceftriaxone | 20 | Cefuroxime | 19 | 4 | Cefitoren | 3 |
| | | CH not donea | 1 | Cefuroxime | 1 |
| | Cefazoline | 2 | CH not donea | 2 | |
| | Cefuroxime | 2 | Cefuroxime | 1 | Cefuroxime | 1 |
| | | CH not donea | 1 | |
| | Meropenem | 4 | Meropenem | 4 | |
| | Imipenem | 2 | Meropenem | 2 | |
| | Piperacillin/tazobactam | 1 | Piperacillin/tazobactam | 1 | 1 | Piperacillin | 1 |
| | Does not remember | 8 | Penicillin | 1 | 60 | Penicillin | 33 |
| | | Amoxicilloyl | 6 | Amoxicilloyl | 22 |
| | | CH not donea | 1 | Amoxicilloyl | 3 |
| | | | 1 | CH not donea | 2 |

Notes: aCH not done due to positive skin test. bCH not done due to anaphylaxis with sIgE positive.
Abbreviation: CH, challenge.
In contrast, this phenomenon occurs despite due to the clinical histories, anaphylaxis was observed. Bourcy et al demonstrated and the fact that 29 patients had been diagnosed by an Allergist, led us to undertake this study.

The profile of our cases reflects variations of the antibiotics use and allergological response according to age: we found patients, especially among the older group, who had reactions with penicillins and positive results to poly-L-lysine, MDM, and/or penicillin, amoxicillin, ampicillin or amoxicillin/clavulanic acid. These correspond to common reactions to BPO, the main determinant generated by benzylpenicillin. On the other hand, we observed many patients in the 60–79-year-old group with BL-selective reactions to the side chain due to the more frequent prescription and use of amoxicillin, amoxicillin/clavulanic and ampicillin than BP. These patients reacted exclusively to amoxicillin, ampicillin or amoxicillin/clavulanic acid but were negative to both penicillin and its major and minor determinants. Positivity to ampicillin in our study was probably due to cross-reactivity with amoxicillin, as reported previously. There were also patients who reacted to cephalosporins, mainly in the younger group, who also had side chain-specific reactions, as previously reported.

In participants’ clinical histories, anaphylaxis was much more frequent in group A than in B, which is logical in light of the different reactions described above. In side chain-specific reactions, authors have observed that anaphylaxis is much more frequent than in classical benzylpenicillin cross-reactors, although this clinical entity occurs in both groups.

A total of 286 patients aged 60 to 79 years and 279 aged 80 years or older completed the study, and 26.9% and 5.4%, respectively, were confirmed as having a BL allergy (p<0.01). Most participants showed good tolerance to penicillins and other BLs like cephalosporins (ceftriaxone, cefazoline, cefotaxime, cefuroxime). The natural loss of sensitization is one possible explanation for these findings, as this has been reported to occur more quickly in side chain-specific reactions like those to amoxicillin or cephalosporins. In contrast, this phenomenon occurs more slowly for BPO-common reactions, also known to be cross-reactive within the penicillin group.

The levels and function of different immunoglobulin isotypes have been studied in detail in the elderly. In murine models, Turner et al demonstrated that changes in the architecture of the lymph node and the spleen impaired the production of antibodies. Bourcy et al demonstrated the expansion of B-cell clones containing mostly IgM or IgA isotypes, which were unable to differentiate between function and non-functioning receptors. Sugahara et al have shown that in humans, the levels and binding capacity of IgA did not change with age, but its affinity decreased, apparently due to the loss of the function of the T lymphocytes in promoting antigen-specific IgA response via differentiation to T follicular helper cells. Regarding IgE however, an extensive literature search yielded no studies concerning the decline in this immunoglobulin response, particularly that related to IgE and drug HSR.

It is reasonable to think that, as with the other antibody isotypes, the decrease in the humoral response could entail a decrease in the affinity of IgE for the antigens, which would lead to unresponsiveness. This could explain why patients with IHSR do not develop reactions after re-exposure to BLs. Although this is a strong hypothesis, new studies on IgE production, regulation and response in elderly people allergic to beta-lactams are necessary to clarify it. Regarding NIHSR, in our study, nine cases were previously confirmed by an allergist by DCT, four of these patients (group A) had positive results in DCT. Evidence suggests that T cell responses persist for a long time, with positive skin tests at the delayed intradermal reading. Thus, it is no surprise that we found patients with positive responses despite the time elapsed. However, the lower response in the older group may also be related to immunosenescence.

Regarding resensitization, we observed only 1.6% positivity after challenge with BLs. Considering that the rate of resensitization does not exceed that in healthy patients treated with BLs, retesting should not be routine as this is rather uncommon, and is recommended only in cases in which there is a high suspicion of IgE-mediated HSRs with negative ST and good tolerance verified in the DCT.

One of the major problems in this population are bacterial infections, stemming from diminished humoral and cellular immunity. Therefore, patients labeled as allergic to BL are of particular concern and have attracted
special attention because they may be deprived of treatments with these antibiotics, as Trubiano et al and others have pointed out. According to our results, older people could benefit from treatment with BLs if aging contributes to the loss of sensitivity, avoiding exposure to more toxic antibiotics like vancomycin and quinolones among others.

The main weakness of this study is that not all cases labelled as allergic in the past had a confirmed diagnosis. On the other hand, 45.6% of patients aged 80 years or older did not remember the event that led to the diagnosis of allergy (median 30 years earlier), so it was not possible to classify HSRs accurately. Therefore, allergological diagnosis cannot be established exclusively with the data collected in the clinical history as reported in previous studies.

The results of the multivariable analysis showed that the risk of allergy to BLs is lower in older patients. The logistic regression analysis showed that a history of anaphylaxis is a predictor of positive results in ST and should be taken into account when exposing patients to BLs again.

Conclusion
To our knowledge, this is the first allergological study conducted in elderly people. Allergy to BLs was confirmed in a low percentage of patients claiming to be allergic, being rare in the elderly over 80 years. It is known that a false labeling of allergies and spontaneous loss of sensitivity to BLs over time are facts related to this, but we describe for the first time that patients with a confirmed diagnosis in the past do not respond when they are re-exposed, this could be justified by the immunosenescence. However, considering this is an observational study, future experimental studies to elucidate what is happening in relation to the production and functioning of IgE during immunosenescence could help to generate more knowledge of beta-lactam allergy in the elderly.

Acknowledgments
The authors would like to thank Ms Meggan Harris and Dr Alexis Lara Rivero for the English edition of the manuscript.

Disclosure
Prof. Dr Javier Fernandez-Sanchez reports a grant from Carlos III Institute: RD16/06/032, during the conduct of the study. The authors report no other conflicts of interest in this work.
59. Trubiano J, Phillips E. Antimicrobial stewardship’s new weapon? A review of antibiotic allergy and pathways to “de-labeling.”. Curr Opin Infect Dis. 2013;26(6):526–537. doi:10.1097/QCO.0000000000000066

60. Hjortlund J, Mortz CG, Skov PS, Bindslev-Jensen C. Diagnosis of penicillin allergy revisited: the value of case history, skin testing, specific IgE and prolonged challenge. Allergy. 2013;68(8):1057–1064. doi:10.1111/all.2013.68.issue-8